{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:05:03Z","timestamp":1773428703912,"version":"3.50.1"},"reference-count":76,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Animals"],"abstract":"<jats:p>Nerve Growth Factor (NGF) is a neurotrophin essential for the maintenance and growth of sensory and sympathetic nerve fibers. In pathological conditions, NGF is widely implicated in peripheral and central sensitization mechanisms, significantly contributing to the genesis and maintenance of chronic pain. Anti-NGF monoclonal antibodies, developed for the management of osteoarthritis pain, have demonstrated clinical efficacy and good tolerability in several animal species, particularly dogs and cats. Although their use is currently limited to the management of osteoarthritis pain, preclinical and clinical evidence indicates their potential therapeutic role in other pathological conditions characterized by chronic pain, such as oncological conditions like osteosarcoma, idiopathic cystitis, inflammatory bowel disease, and neuropathies. This review aims to provide an updated overview of the potential clinical applications of anti-NGF monoclonal antibodies beyond osteoarthritis, analyzing their pathophysiological rationale, available scientific evidence, possible therapeutic advantages, and limitations that remain to be addressed.<\/jats:p>","DOI":"10.3390\/ani15223243","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:47:27Z","timestamp":1762775247000},"page":"3243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond Osteoarthritis: Emerging Applications of Anti-NGF Monoclonal Antibodies in Pain Management in Dogs and Cats"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-5469","authenticated-orcid":false,"given":"Giorgia","family":"della Rocca","sequence":"first","affiliation":[{"name":"Department of Veterinary Medicine, University of Perugia, 06126 Perugia, Italy"},{"name":"Research Center on Animal Pain (CeRiDA), University of Perugia, 06126 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9053-2139","authenticated-orcid":false,"given":"Stefano","family":"Coaccioli","sequence":"additional","affiliation":[{"name":"Italian Association for the Study of Pain (AISD), 00193 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-5853","authenticated-orcid":false,"given":"Alessandra","family":"Di Salvo","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Perugia, 06126 Perugia, Italy"},{"name":"Research Center on Animal Pain (CeRiDA), University of Perugia, 06126 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0166-2236(96)10058-8","article-title":"Nerve Growth Factor: From Neurotrophin to Neurokine","volume":"19","author":"Skaper","year":"1996","journal-title":"Trends Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2005.12.001","article-title":"Novel Class of Pain Drugs Based on Antagonism of NGF","volume":"27","author":"Hefti","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of Pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"della Rocca, G., and Gamba, D. (2021). Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?. Animals, 11.","DOI":"10.3390\/ani11040952"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jsap.13495","article-title":"Advances in the Pharmaceutical Treatment Options for Canine Osteoarthritis","volume":"63","author":"Pye","year":"2022","journal-title":"J. Small Anim. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Baker-Meuten, A., Wendland, T., Shamir, S.K., Hess, A.M., and Duerr, F.M. (2020). Evaluation of Acupuncture for the Treatment of Pain Associated with Naturally-Occurring Osteoarthritis in Dogs: A Prospective, Randomized, Placebo-Controlled, Blinded Clinical Trial. BMC Vet. Res., 16.","DOI":"10.1186\/s12917-020-02567-1"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gatta, C., Calzaretta, G., Musco, N., Aragosa, F., Cavalli, S., Damiano, S., Lombardi, P., Ferrentino, A., Lotito, D., and Della Valle, G. (2025). Laser Acupuncture Effects on Chronic Pain, Inflammatory Response, and Biochemical and Oxidative Stress Markers in Osteoarthritic Dogs: A Randomized Controlled Trial. Animals, 15.","DOI":"10.3390\/ani15172568"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/vms3.997","article-title":"Effects of Low-level Laser Therapy on Impaired Mobility in Dogs with Naturally Occurring Osteoarthritis","volume":"9","author":"Barale","year":"2023","journal-title":"Vet. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/vms3.182","article-title":"Effects of a Nutritional Supplement in Dogs Affected by Osteoarthritis","volume":"5","author":"Musco","year":"2019","journal-title":"Vet. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amato, R., Pacifico, E., Lotito, D., Iervolino, V., Pierantoni, L., Cortese, L., Musco, N., Lombardi, P., Mastellone, V., and Pero, M.E. (2025). Effects of a Cannabinoid-Based Phytocomplex (Pain ReliefTM) on Chronic Pain in Osteoarthritic Dogs. Animals, 15.","DOI":"10.3390\/ani15010101"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cachon, T., Frykman, O., Innes, J.F., Lascelles, B.D.X., Okumura, M., Sousa, P., Staffieri, F., Steagall, P.V., and Van Ryssen, B. (2023). COAST Development Group\u2019s International Consensus Guidelines for the Treatment of Canine Osteoarthritis. Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1137888"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/vr.104590","article-title":"Anti-nerve Growth Factor Monoclonal Antibodies for the Control of Pain in Dogs and Cats","volume":"184","author":"Enomoto","year":"2019","journal-title":"Vet. Rec."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious Joint-Related Adverse Events in Randomized Controlled Trials of Anti-Nerve Growth Factor Monoclonal Antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kan, S.-L., Li, Y., Ning, G.-Z., Yuan, Z.-F., Chen, L.-X., Bi, M.-C., Sun, J.-C., and Feng, S.-Q. (2016). Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157105"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.joca.2023.08.010","article-title":"Characterization of Adverse Joint Outcomes in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab","volume":"31","author":"Carrino","year":"2023","journal-title":"Osteoarthr. Cartil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3415\/VCOT-10-04-0051","article-title":"Nerve Growth Factor Concentrations in the Synovial Fluid from Healthy Dogs and Dogs with Secondary Osteoarthritis","volume":"24","author":"Isola","year":"2011","journal-title":"Vet. Comp. Orthop. Traumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gearing, D.P., Virtue, E.R., Gearing, R.P., and Drew, A.C. (2013). A Fully Caninised Anti-NGF Monoclonal Antibody for Pain Relief in Dogs. BMC Vet. Res., 9.","DOI":"10.1186\/1746-6148-9-226"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2460\/ajvr.75.6.532","article-title":"Canine Brief Pain Inventory Scores for Dogs with Osteoarthritis before and after Administration of a Monoclonal Antibody against Nerve Growth Factor","volume":"75","author":"Webster","year":"2014","journal-title":"Am. J. Vet. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lascelles, B.D.X., Knazovicky, D., Case, B., Freire, M., Innes, J.F., Drew, A.C., and Gearing, D.P. (2015). A Canine-Specific Anti-Nerve Growth Factor Antibody Alleviates Pain and Improves Mobility and Function in Dogs with Degenerative Joint Disease-Associated Pain. BMC Vet. Res., 11.","DOI":"10.1186\/s12917-015-0413-x"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaa.2021.08.001","article-title":"A Prospective, Randomized, Blinded, Placebo-Controlled Multisite Clinical Study of Bedinvetmab, a Canine Monoclonal Antibody Targeting Nerve Growth Factor, in Dogs with Osteoarthritis","volume":"48","author":"Corral","year":"2021","journal-title":"Vet. Anaesth. Analg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaa.2023.06.003","article-title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Multisite, Parallel-Group Field Study in Dogs with Osteoarthritis Conducted in the United States of America Evaluating Bedinvetmab, a Canine Anti-Nerve Growth Factor Monoclonal Antibody","volume":"50","author":"Michels","year":"2023","journal-title":"Vet. Anaesth. Analg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gildea, E., North, C., Walker, K., Adriaens, F., and Lascelles, B.D.X. (2024). Use of Bedinvetmab (Librela\u00ae) for Canine Osteoarthritis in France, Germany, Italy, Spain, and the UK: Quantitative Analysis of Veterinarian Satisfaction and Real-World Treatment Patterns. Animals, 14.","DOI":"10.3390\/ani14152231"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Innes, J.F., Lascelles, B.D.X., Bell, D., Tulloch, R., McVey, A., Northcott, C., Welbourn, M., Higgins, K., Horakova, V., and Maddox, T.W. (2025). A Randomised, Parallel-Group Clinical Trial Comparing Bedinvetmab to Meloxicam for the Management of Canine Osteoarthritis. Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1502218"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105733","DOI":"10.1016\/j.tvjl.2021.105733","article-title":"Laboratory Safety Evaluation of Bedinvetmab, a Canine Anti-Nerve Growth Factor Monoclonal Antibody, in Dogs","volume":"276","author":"Krautmann","year":"2021","journal-title":"Vet. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Monteiro, B.P., Simon, A., Knesl, O., Mandello, K., Nederveld, S., Olby, N.J., Innes, J.F., and Lascelles, B.D.X. (2025). Global Pharmacovigilance Reporting of the First Monoclonal Antibody for Canine Osteoarthritis: A Case Study with Bedinvetmab (LibrelaTM). Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1558222"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Farrell, M., Waibel, F.W.A., Carrera, I., Spattini, G., Clark, L., Adams, R.J., Von Pfeil, D.J.F., De Sousa, R.J.R., Villagr\u00e0, D.B., and Amengual-Vila, M. (2025). Musculoskeletal Adverse Events in Dogs Receiving Bedinvetmab (Librela). Front. Vet. Sci., 12.","DOI":"10.3389\/fvets.2025.1581490"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.vaa.2024.11.041","article-title":"A Case of Potential Rapidly Progressing Osteoarthritis in a Dog during Bedinvetmab Treatment","volume":"52","author":"Iff","year":"2025","journal-title":"Vet. Anaesth. Analg."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Reid, J., Gildea, E., Davies, V., Thompson, J., and Scott, M. (2024). Measuring the Effect of the Anti-Nerve Growth Factor Antibodies Bedinvetmab and Frunevetmab on Quality of Life in Dogs and Cats with Osteoarthritis Using a Validated Health-Related Quality of Life Outcome Measure: An Observational Real-World Study. Front. Vet. Sci., 11.","DOI":"10.3389\/fvets.2024.1395360"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/jvim.13985","article-title":"In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats","volume":"30","author":"Gearing","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/jvim.13972","article-title":"A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease\u2013Associated Pain: A Pilot Proof of Concept Study","volume":"30","author":"Gruen","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Walters, R.R., Boucher, J.F., and De Toni, F. (2021). Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration. Front. Vet. Sci., 8.","DOI":"10.3389\/fvets.2021.687448"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gruen, M.E., Myers, J.A.E., and Lascelles, B.D.X. (2021). Efficacy and Safety of an Anti-Nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study. Front. Vet. Sci., 8.","DOI":"10.3389\/fvets.2021.610028"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/jvim.16291","article-title":"Frunevetmab, a Felinized anti-nerve Growth Factor Monoclonal Antibody, for the Treatment of Pain from Osteoarthritis in Cats","volume":"35","author":"Gruen","year":"2021","journal-title":"J. Vet. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1055\/s-0044-1788038","article-title":"Activity Levels in Seven Cats with Osteoarthritis Monitored by GPS Tracker Following Frunevetmab Injection","volume":"7","author":"Power","year":"2024","journal-title":"VCOT Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/rheumatology\/keq188","article-title":"Angiogenesis and Nerve Growth Factor at the Osteochondral Junction in Rheumatoid Arthritis and Osteoarthritis","volume":"49","author":"Walsh","year":"2010","journal-title":"Rheumatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100504","DOI":"10.1016\/j.ocarto.2024.100504","article-title":"Increased Nerve Growth Factor Expression and Osteoclast Density Are Associated with Subchondral Bone Marrow Lesions in Osteoarthritic Knees","volume":"6","author":"Aso","year":"2024","journal-title":"Osteoarthr. Cartil. Open"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"MacDonald, I.J., Liu, S.-C., Su, C.-M., Wang, Y.-H., Tsai, C.-H., and Tang, C.-H. (2018). Implications of Angiogenesis Involvement in Arthritis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072012"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/JPR.S302004","article-title":"The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain","volume":"14","author":"Bimonte","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1939-1676.2008.0151.x","article-title":"Investigating TrkA Expression in Canine Appendicular Osteosarcoma","volume":"22","author":"Fan","year":"2008","journal-title":"J. Vet. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1006\/bbrc.1994.1127","article-title":"Expression of Nerve Growth Factor Family Neurotrophins in a Mouse Osteoblastic Cell Line","volume":"198","author":"Nakanishi","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1006\/bbrc.1994.2319","article-title":"Expression of TrkC in a Mouse Osteoblastic Cell Line and Its Response to Neurotrophin-3","volume":"203","author":"Nakanishi","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1006\/bbrc.1994.2791","article-title":"NGF Stimulates Differentiation of Osteoblastic MC3T3-E1 Cells","volume":"205","author":"Yada","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0024-3205(00)00705-0","article-title":"Anti-Apoptotic Action of Nerve Growth Factor in Mouse Osteoblastic Cell Line","volume":"67","author":"Mogi","year":"2000","journal-title":"Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0959-8049(01)00190-3","article-title":"An Anti-Apoptotic Role for NGF Receptors in Human Rhabdomyosarcoma","volume":"37","author":"Astolfi","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0736-5748(00)00041-1","article-title":"Nerve Growth Factor (NGF) Influences Differentiation and Proliferation of Myogenic Cells in Vitro via TrKA","volume":"18","author":"Rende","year":"2000","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/01.cad.0000224459.13651.fd","article-title":"Role of Nerve Growth Factor and Its Receptors in Non-Nervous Cancer Growth: Efficacy of a Tyrosine Kinase Inhibitor (AG879) and Neutralizing Antibodies Antityrosine Kinase Receptor A and Antinerve Growth Factor: An in-Vitro and in-Vivo Study","volume":"17","author":"Rende","year":"2006","journal-title":"Anticancer Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/039463201302600306","article-title":"Growth Factors, Their Receptor Expression and Markers for Proliferation of Endothelial and Neoplastic Cells in Human Osteosarcoma","volume":"26","author":"Bianchi","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2094","DOI":"10.1590\/0100-6991e-20192094","article-title":"Express\u00e3o de Neurotrofinas e de Seus Receptores No Osteossarcoma Prim\u00e1rio","volume":"46","author":"Antunes","year":"2019","journal-title":"Rev. Col. Bras. Cir."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.7150\/ijbs.95463","article-title":"Nerve Growth Factor Promote VCAM-1-Dependent Monocyte Adhesion and M2 Polarization in Osteosarcoma Microenvironment: Implications for Larotrectinib Therapy","volume":"20","author":"Lin","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41419-024-06752-0","article-title":"Targeting Nerve Growth Factor-Mediated Osteosarcoma Metastasis: Mechanistic Insights and Therapeutic Opportunities Using Larotrectinib","volume":"15","author":"Hou","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Hou, S.-M., Cheng, C.-Y., Chen, W.-L., Chang, E.-M., and Lin, C.-Y. (2025). NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via MiR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib. Life, 15.","DOI":"10.3390\/life15010099"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.pain.2011.07.020","article-title":"Preventive or Late Administration of Anti-NGF Therapy Attenuates Tumor-Induced Nerve Sprouting, Neuroma Formation, and Cancer Pain","volume":"152","author":"Ghilardi","year":"2011","journal-title":"Pain"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1268","DOI":"10.1093\/oncolo\/oyad188","article-title":"A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects with Cancer Pain Due to Bone Metastasis","volume":"28","author":"Fallon","year":"2023","journal-title":"Oncologist"},{"key":"ref_54","unstructured":"Vigevani, N., Gurney, M., and Purzycka, K. (2022, January 12). Palliative Treatment of Primary Bone Tumours in Dogs: A Case Series of 6 Dogs Treated with Bedinvetmab, Zoledronate and Analgesics. Proceedings of the Veterinary and Comparative Oncology, Sicily, Italy."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1152\/ajpregu.00728.2007","article-title":"Blockade of NGF and Trk Receptors Inhibits Increased Peripheral Mechanical Sensitivity Accompanying Cystitis in Rats","volume":"295","author":"Guerios","year":"2008","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpuro0408","article-title":"Mechanisms of Disease: The Role of Nerve Growth Factor in the Pathophysiology of Bladder Disorders","volume":"3","author":"Steers","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_57","first-page":"243","article-title":"Crosstalk between the Immune System and Neural Pathways in Interstitial Cystitis\/Bladder Pain Syndrome","volume":"25","author":"Duh","year":"2018","journal-title":"Discov. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1464-410X.2009.08675.x","article-title":"Urinary Nerve Growth Factor Level Is Increased in Patients with Interstitial Cystitis\/Bladder Pain Syndrome and Decreased in Responders to Treatment","volume":"104","author":"Liu","year":"2009","journal-title":"BJU Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1464-410X.2012.11672.x","article-title":"Nerve Growth Factor (NGF): A Potential Urinary Biomarker for Overactive Bladder Syndrome (OAB)?","volume":"111","author":"Seth","year":"2013","journal-title":"BJU Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.17219\/acem\/69231","article-title":"Urine Nerve Growth Factor (NGF) Level, Bladder Nerve Staining and Symptom\/Problem Scores in Patients with Interstitial Cystitis","volume":"27","author":"Tonyali","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/1570159X17666190617095844","article-title":"Partners in Crime: NGF and BDNF in Visceral Dysfunction","volume":"17","author":"Coelho","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.juro.2015.10.178","article-title":"Tanezumab Reduces Pain in Women with Interstitial Cystitis\/Bladder Pain Syndrome and Patients with Nonurological Associated Somatic Syndromes","volume":"195","author":"Nickel","year":"2016","journal-title":"J. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/nau.20747","article-title":"Beyond Neurons: Involvement of Urothelial and Glial Cells in Bladder Function","volume":"29","author":"Birder","year":"2010","journal-title":"Neurourol. Urodyn."},{"key":"ref_64","first-page":"47","article-title":"Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis","volume":"16","author":"Mykoniatis","year":"2022","journal-title":"Biologics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/nau.25547","article-title":"The Efficacy and Safety of Monoclonal Antibody Therapies for Interstitial Cystitis\/Bladder Pain Syndrome: A Meta-analysis of Randomized Controlled Trials","volume":"43","author":"Cao","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"612","DOI":"10.5056\/jnm20151","article-title":"A Pilot Study of Clinical Evaluation and Formation Mechanism of Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease Patients in Remission","volume":"27","author":"Wang","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_67","first-page":"1009","article-title":"Dextran Sodium Sulphate (DSS)-Induced Colitis Alters the Expression of Neurotrophins in Smooth Muscle Cells of Rat Colon","volume":"66","author":"Shammala","year":"2017","journal-title":"Physiol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/gast.2000.9307","article-title":"Protective Role of Neurotrophins in Experimental Inflammation of the Rat Gut","volume":"119","author":"Reinshagen","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2005.064063","article-title":"Interactive Involvement of Brain Derived Neurotrophic Factor, Nerve Growth Factor, and Calcitonin Gene Related Peptide in Colonic Hypersensitivity in the Rat","volume":"55","author":"Delafoy","year":"2006","journal-title":"Gut"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1111\/nmo.12199","article-title":"Peripheral Contribution of NGF and ASIC 1a to Colonic Hypersensitivity in a Rat Model of Irritable Bowel Syndrome","volume":"25","author":"Matricon","year":"2013","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/FBP.0000000000000246","article-title":"Nerve Growth Factor Induces Facial Heat Hyperalgesia and Plays a Role in Trigeminal Neuropathic Pain in Rats","volume":"27","author":"Kopruszinski","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jocn.2006.09.002","article-title":"Burning Mouth Syndrome as a Trigeminal Small Fibre Neuropathy: Increased Heat and Capsaicin Receptor TRPV1 in Nerve Fibres Correlates with Pain Score","volume":"14","author":"Yilmaz","year":"2007","journal-title":"J. Clin. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1601-0825.2009.01648.x","article-title":"Neuropeptides in Saliva of Subjects with Burning Mouth Syndrome: A Pilot Study","volume":"16","author":"Borelli","year":"2010","journal-title":"Oral Dis."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Kouri, M., Adamo, D., Vardas, E., Georgaki, M., Canfora, F., Mignogna, M.D., and Nikitakis, N. (2024). Small Fiber Neuropathy in Burning Mouth Syndrome: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111442"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/revneuro-2022-0037","article-title":"Involvement of Nerve Growth Factor (NGF) in Chronic Neuropathic Pain\u2014A Systematic Review","volume":"34","author":"Reis","year":"2023","journal-title":"Rev. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s12035-020-02156-1","article-title":"NGF-Induced Nav1.7 Upregulation Contributes to Chronic Post-Surgical Pain by Activating SGK1-Dependent Nedd4-2 Phosphorylation","volume":"58","author":"Liu","year":"2021","journal-title":"Mol. Neurobiol."}],"container-title":["Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2615\/15\/22\/3243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:07:29Z","timestamp":1762776449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2615\/15\/22\/3243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":76,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ani15223243"],"URL":"https:\/\/doi.org\/10.3390\/ani15223243","relation":{},"ISSN":["2076-2615"],"issn-type":[{"value":"2076-2615","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]}}}